Want to see IT:PHN full AI Analyst Report?
Top Page
PharmaNutra SpA
(PHN)
Select Model
Select Model
Rating:59Neutral
Price Target:
€81.00
▼(-1.82% Downside)
Action:Reiterated
Date:09/17/26
The score is primarily driven by mixed financial performance: steady revenue growth, solid cash generation, improving leverage, and strong ROE are offset by the notable TTM deterioration in operating profitability and weaker gross margin. Technicals further pressure the score as the stock trades below key moving averages with negative MACD. Valuation is also a restraint due to a high P/E and only modest dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for PharmaNutra’s branded nutraceuticals and related formulations. Growth across multiple years supports broader market reach and provides a durable foundation for future earnings, assuming the company can preserve profitability as sales scale.
Negative Factors
Negative Operating Profitability
The shift from positive to negative operating profitability is a material threat to earnings quality and margin sustainability. If it persists, revenue growth may generate less value, weaken cash conversion, and constrain the company’s ability to reinvest in products, distribution, and partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion indicates continued demand for PharmaNutra’s branded nutraceuticals and related formulations. Growth across multiple years supports broader market reach and provides a durable foundation for future earnings, assuming the company can preserve profitability as sales scale.
Read all positive factors
PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€707.68M
Dividend Yield1.69%
Average Volume (3M)18.04K
Price to Earnings (P/E)32.7
Beta (1Y)0.40
Revenue Growth17.69%
EPS Growth23.06%
CountryIT
Employees140
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.18
Shares Outstanding9,680,977
10 Day Avg. Volume27,049
30 Day Avg. Volume18,035
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.00Price Target Upside17.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.59
Revenue Forecast (FY)€156.10M
PharmaNutra SpA Business Overview & Revenue Model
Company Description
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europ...
How the Company Makes Money
PharmaNutra makes money primarily by selling nutraceutical and dietary supplement products and related formulations through two main channels: (1) sales of its own branded products to distributors, pharmacies, and other commercial partners in its ...
PharmaNutra SpA Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 142.88M | 131.69M | 116.15M | 101.03M | 83.39M | 68.14M |
| Gross Profit | 38.25M | 29.71M | 82.79M | 48.95M | 30.17M | 32.15M |
| EBITDA | -5.02M | 34.21M | 32.01M | 26.53M | 24.61M | 19.84M |
| Net Income | 20.74M | 20.00M | 16.61M | 12.83M | 15.05M | 13.77M |
Balance Sheet | ||||||
| Total Assets | 120.90M | 125.23M | 117.47M | 112.44M | 100.16M | 71.36M |
| Cash, Cash Equivalents and Short-Term Investments | 15.14M | 30.61M | 29.10M | 25.12M | 26.86M | 33.94M |
| Total Debt | 18.36M | 20.51M | 24.27M | 28.02M | 17.73M | 6.35M |
| Total Liabilities | 51.37M | 53.99M | 55.27M | 58.04M | 49.21M | 26.27M |
| Stockholders Equity | 69.67M | 71.35M | 62.16M | 54.41M | 50.95M | 45.08M |
Cash Flow | ||||||
| Free Cash Flow | 15.02M | 16.43M | 16.25M | -1.16M | -8.69M | 15.43M |
| Operating Cash Flow | 19.08M | 19.56M | 20.50M | 12.09M | 14.47M | 20.41M |
| Investing Cash Flow | -3.42M | -3.36M | -2.21M | -14.70M | -23.71M | -5.54M |
| Financing Cash Flow | -17.39M | -13.12M | -21.59M | -516.00K | 1.89M | -1.92M |
PharmaNutra SpA Technical Analysis
Negative
82.50
Price Trends
80.00
Negative
84.15
Negative
75.82
Negative
Market Momentum
-2.54
Positive
40.98
Neutral
46.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Negative. The current price of 82.5 is above the 20-day moving average (MA) of 75.75, above the 50-day MA of 80.00, and above the 200-day MA of 75.82, indicating a bearish trend. The MACD of -2.54 indicates Positive momentum. The RSI at 40.98 is Neutral, neither overbought nor oversold. The STOCH value of 46.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHN.
PharmaNutra SpA Peers Comparison
UnderperformOutperform
Sector (51)
IT:PHN
PharmaNutra SpA
71.20
25.06
54.33%
IT:GHC
Garofalo Health Care S.P.A.
5.38
0.42
8.45%
IT:ARBS
Arterra Bioscience SpA
2.85
0.19
7.02%
IT:EUK
Eukedos S.p.A.
0.57
-0.15
-20.98%
IT:COSMO
Farmacosmo S.P.A.
0.44
-0.03
-5.76%
IT:SVS
Svas Biosana S.p.A.
8.00
-0.31
-3.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.